新诊断2型糖尿病中C反应蛋白、C肽与首次心血管事件及死亡风险:丹麦队列研究
在丹麦2型糖尿病战略研究中心前瞻性队列中,近期诊断2型糖尿病患者检测超敏C反应蛋白(hs-CRP,n=7,301)和C肽(n=5,765)。中位随访4.8年,hs-CRP>3 mg/L较<1 mg/L与心血管事件风险升高相关(aHR 1.45),全因死亡风险更高(aHR 2.47);hs-CRP与C肽均高者风险最高。
要点
- hs-CRP>3 mg/L较<1 mg/L与心血管事件风险升高相关(aHR 1.45,95%CI 1.07-1.96)。
- hs-CRP>3 mg/L较<1 mg/L与全因死亡风险升高相关(aHR 2.47,95%CI 1.88-3.25)。
- hs-CRP≤3 mg/L且C肽<1,470 pmol/L者相比,两者均高者心血管事件和全因死亡风险最高。
核心结论
- hs-CRP作为全因死亡预后生物标志物强于心血管事件,可能有助于早期发现和预防心血管事件以外的致死性疾病。
- C肽升高是强心血管事件生物标志物,支持在2型糖尿病心血管事件预防中针对高胰岛素血症/胰岛素抵抗。
研究设计与样本
- 丹麦2型糖尿病战略研究中心前瞻性队列研究,近期诊断2型糖尿病患者检测血清hs-CRP(n=7,301)和C肽(n=5,765)。
- 无既往心血管事件患者(n=6,407)随访至首次心肌梗死、卒中、冠状动脉血运重建或心血管死亡,全部患者(n=7,301)随访全因死亡。
- 采用Cox回归计算校正风险比(aHR),并检验hs-CRP与C肽的交互作用。
主要发现
- 中位随访4.8年,hs-CRP>3 mg/L较<1 mg/L与心血管事件风险升高相关(aHR 1.45,95%CI 1.07-1.96)。
- hs-CRP>3 mg/L较<1 mg/L与全因死亡风险升高相关(aHR 2.47,95%CI 1.88-3.25)。
- 与hs-CRP≤3 mg/L且C肽<1,470 pmol/L者相比,两者均高者心血管事件风险最高(aHR 1.61,95%CI 1.10-2.34),全因死亡风险也最高(aHR 2.36,95%CI 1.73-3.21)。
- 在高C肽患者中,心血管事件风险不因hs-CRP低或高而异,但全因死亡风险有差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigated the relationship between hs-CRP, a marker of low-grade inflammation, alone or in combination with C-peptide, a marker of hyperinsulinemia/insulin resistance, and risk for cardiovascular events (CVEs) and mortality in patients recently diagnosed with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In patients with recent-onset T2D, we measured serum hs-CRP (n = 7,301) and C-peptide (n = 5,765) in the prospective Danish Centre for Strategic Research in Type 2 Diabetes cohort study. Patients with no prior CVE (n = 6,407) were followed until first myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and all patients (n = 7,301) were followed for all-cause mortality. We computed adjusted hazard ratios (aHRs) by Cox regression and tested for the interaction between hs-CRP and C-peptide. RESULTS: During follow-up (median 4.8 years), high (>3 mg/L) versus low (<1 mg/L) hs-CRP was associated with increased CVE risk (aHR 1.45 [95% CI 1.07-1.96]) and with even greater risk of all-cause mortality (2.47 [1.88-3.25]). Compared with patients with low hs-CRP (≤3 mg/L) and low C-peptide (<1,470 pmol/L), those with high levels of both biomarkers had the highest CVE (1.61 [1.10-2.34]) and all-cause mortality risk (2.36 [1.73-3.21]). Among patients with high C-peptide, risk of CVEs did not differ by low or high hs-CRP, whereas risk of all-cause mortality did. CONCLUSIONS: The finding of high hs-CRP as a stronger prognostic biomarker of all-cause mortality than of CVEs may facilitate improved early detection and prevention of deadly diseases besides CVEs. Conversely, elevated C-peptide as a strong CVE biomarker supports the need to target hyperinsulinemia/insulin resistance in T2D CVE prevention.
引用
- Gedebjerg A, Bjerre M, Kjaergaard AD, et al. CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes: A Danish Cohort Study. Diabetes Care. 2023. PMID: 36930691. doi:10.2337/dc22-1353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。